

INDEX

A

- Acquired immunodeficiency syndrome (AIDS), primary central nervous system lymphoma related to, **665-687**
 diagnostic considerations, 671-674
 baseline evaluations, 671-672
 biopsy for, 698-699
 early biopsy *versus* empiric toxoplasmosis therapy, 673-674
 evaluation of cerebrospinal fluid, 672-673
 epidemiology and link with Epstein-Barr virus, 666-667
 histopathology, 667
 radiographic features, 667-671, 693-694
 CT and MRI assessment, 667-670
 metabolic imaging, 670-671
 treatment options, 674-681
 antiretroviral therapy, 674-675
 chemotherapy and combined modality therapy, 675-678
 Epstein-Barr virus-targeted therapies, 679-681
 radiation therapy, 674
- Age, as prognostic factor in primary central nervous system lymphoma, 630-631
 at diagnosis of primary central nervous system lymphoma, 689
- AIDS. See *Acquired immunodeficiency syndrome*.
- Algorithm, for treatment of primary intraocular lymphoma, 744-746
- Anatomic distribution, of lesions in primary central nervous system lymphoma, 690-91
- Angiography, fluorescein, in diagnosis of primary intraocular lymphoma, 741
- Antiepileptic medications, for seizures in primary central nervous system lymphoma, 623
- Antiretroviral therapy, for AIDS-related primary central nervous system lymphoma, 674-675
- Autologous stem cell transplantation, for central nervous system involvement in non-Hodgkin's lymphoma, 605-606
 with intensive chemotherapy for primary central nervous system lymphoma, 722-725

B

- B-cell primary central nervous system lymphoma, indolent, 661-662
- Biopsy, in diagnosis of primary central nervous system lymphoma, 698-699
 in AIDS patients, 673-674, 698-699
 in immunocompetent patients, 698
 vitreous, in diagnosis of primary intraocular lymphoma, 742
- Blood-brain barrier disruption, enhancement of chemotherapy by, in primary central nervous system lymphoma, 725
- Bone marrow transplantation, for primary central nervous system lymphoma, 622-623
- Brain delivery, of chemotherapy, enhancement of by blood-brain barrier disruption in primary central nervous system lymphoma, 725

C

- Central nervous system, involvement of, in non-Hodgkin's lymphoma, **597-609**
 diagnosis, 600-602
 cerebrospinal fluid analysis, 601-602
 neuroimaging, 600-601
 prophylaxis, 602
 risk factors, 599
 treatment, 602-606
 transplantation, 605-606
 relapse to, in lymphoma patients, **751-763**

Note: Page numbers of article titles are in **boldface** type.

- Central nervous system lymphoma, primary, 611-749
- AIDS-related, **665-687**
 - diagnostic considerations, 671-674
 - epidemiology and link with Epstein-Barr virus, 666-667
 - histopathology, 667
 - radiographic features, 667-671
 - treatment options, 674-681
 - clinical features, **689-692**
 - age and gender, 689
 - anatomic distribution of lesions, 690-691
 - predisposing conditions, 690
 - symptoms and signs, 691-692
 - time from symptom onset to diagnosis, 692
 - diagnosis, **692-700**
 - biopsy, 698-699
 - cerebrospinal fluid analysis, 694-697
 - differentials, 692-693
 - neuroimaging, 693-694
 - ocular evaluation, 697-698
 - staging, 699-700
 - indolent B-cell, 661-662
 - new treatment approaches, **719-728**
 - blood-brain barrier disruption and intra-arterial chemotherapy, 725
 - intensive chemotherapy and autologous stem cell transplantation, 722-725
 - Phase II trials of single-agent chemotherapy regimens, 719-721
 - rituximab, 721-722
 - pathology and genetics, **705-717**
 - gross pathology, 706
 - incidence, 705-706
 - microscopic pathology and immunophenotype, 706-707
 - molecular pathology, 712-714
 - pathogenesis, 711-712
 - prognostic factors, 612, **629-649**
 - age and performance status, 630-631
 - new variables with potential value as, 636-643
 - predictors of treatment-related toxicity, 643-645
 - scoring systems for, 631-636
 - T-cell, 658-661
 - treatment, **611-627**
 - bone marrow transplantation, 622-623
 - chemotherapy, 614-622
 - for recurrent, 623
 - radiotherapy alone, 613-614
 - steroids, 612-613
 - symptomatic treatment, 623
 - treatment-related neurotoxicity, **729-738**
 - mechanisms of, 729-730
 - neuroimaging findings, 730-731
 - neurologic and neurocognitive sequelae, 732-735
 - white matter changes and cognitive outcome, 731-732
 - unusual variants of, **651-664**
 - neurolymphomatosis, 652-653
 - primary leptomeningeal lymphoma, 653-657
 - rare pathologic variants, 657-662
- secondary, **751-763**
 - clinical features and diagnosis, 754-755
 - incidence, 751-754
 - outcome after relapse, 758-760
 - prophylaxis for, 760-761
 - risk factors for relapse, 755-758
- Cerebrospinal fluid analysis, in primary central nervous system lymphoma, 694-697
- AIDS-related, 672-673, 697
 - in immunocompetent patients, 695-697
- in suspected central nervous system involvement in non-Hodgkin's lymphoma, 601-602
- Chemotherapy, for central nervous system involvement in non-Hodgkin's lymphoma, 602-604
- for primary central nervous system lymphoma, 614-622
 - AIDS-related, 675-678
 - enhancement of, by blood-brain barrier disruption, 725
 - high-dose methotrexate, 616-622
 - intensive, with autologous stem cell transplantation, 722-725
 - intra-arterial, 725
 - phase II trials of single-agent regimens, 719-721
 - systemic lymphoma regimens, 615-616
 - for primary intraocular lymphoma, 744-746

Download English Version:

<https://daneshyari.com/en/article/10026869>

Download Persian Version:

<https://daneshyari.com/article/10026869>

[Daneshyari.com](https://daneshyari.com)